FDA 483 OBSERVATION · #165 OF 1,923 MOST-CITED
Sufficient space
FDA cited this observation 190 times across 183 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The plant did not provide sufficient space for the placement of equipment and storage of materials as necessary for sanitary operations and the production of safe food — equipment was crowded or materials were stored so densely that cleaning, inspection, and separation of operations were compromised.
Why FDA writes it — Inadequate space forces equipment and materials together, creating uncleanable gaps and cross-contamination between raw and finished operations; congestion blocks access for cleaning and inspection, so the layout itself undermines sanitary control.
- Lay out equipment with enough clearance around and between units to allow cleaning, inspection, and maintenance access.
- Provide adequate space to separate incompatible operations and to segregate raw materials from finished product.
- Store materials off the floor and away from walls with room to clean beneath and behind them.
- Reassess space and traffic flow when adding equipment or products rather than absorbing it into existing congestion.
- Production grew and equipment was added into a footprint designed for a smaller operation, eroding clearances.
- Storage and staging expand into processing aisles, blocking the access that sanitary operation requires.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.5× the rate of the average FDA-cited firm (11.5% vs 7.8%), across 183 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Failure to provide sufficient space for placement of equipment and storage of materials as necessary for the maintenance of sanitary operations and the production of safe food.
Failure to provide sufficient space for storage of materials as necessary for the maintenance of sanitary operations and the production of safe food.
Failure to provide sufficient space for storage of materials as necessary for the maintenance of sanitary operations and the production of safe food.
Failure to provide sufficient space for storage of materials as necessary for the maintenance of sanitary operations and the production of safe food.
Failure to provide sufficient space for placement of equipment and storage of materials as necessary for the maintenance of sanitary operations and the production of safe food.
Failure to provide sufficient space for storage of materials as necessary for the maintenance of sanitary operations and the production of safe food.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →